Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update

- XCARTTM continuing to advance toward IND-enabling studies- PolyXen® platform technology growing royalty stream through license agreement- Closed the year with $18.2 million of cashFRAMINGHAM, MA / ACCESSWIRE / March 23, 2022 / Xenetic Biosciences, …